PARP inhibition results in significant resolution of pulmonary fibrosis in sheep
June 3, 2024
Researchers from Federation University Australia and affiliated organizations have reported data from a study that aimed to assess the therapeutic efficacy of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in a large animal model of pulmonary fibrosis.